Teva Pharmaceutical Industries Limited (NYSE:TEVA) : The highest level Teva Pharmaceutical Industries Limited (NYSE:TEVA) is projected to reach is $100 for the short term and the lowest estimate is at $58. The consolidated price target from 18 rating analysts who initiate coverage on the stock is $74.3 and the possibility the share price can swing is $9.29.
Teva Pharmaceutical Industries Limited has lost 2.22% in the last five trading days and dropped 5.07% in the last 4 weeks. Teva Pharmaceutical Industries Limited has dropped 6.72% during the last 3-month period . Year-to-Date the stock performance stands at -22.5%. Also, Credit Suisse initiates coverage on Teva Pharmaceutical Industries Limited (NYSE:TEVA). The rating major has initiated the coverage with neutral rating on the shares. The Analysts at Credit Suisse announces a current price target of $60 per share. The rating by the firm was issued on May 4, 2016.
Teva Pharmaceutical Industries Limited (NYSE:TEVA) : Zacks Investment Research ranks Teva Pharmaceutical Industries Limited (NYSE:TEVA) as 3, which is a Hold recommendation. 13 research analysts consider that the stocks fundamentals point to a bright future, hence they rate the stock as a Strong Buy. 2 other analysts are mildly bullish on the stock and favor a Buy. A total of 4 analysts believe that the stock has a limited upside, hence they advise a Hold. The average broker rating of 19 research analysts is 1.5, which indicates as a Strong Buy.
Teva Pharmaceutical Industries Limited (NYSE:TEVA): The stock opened at $50.19 on Thursday but the bulls could not build on the opening and the stock topped out at $50.45 for the day. The stock traded down to $49.76 during the day, due to lack of any buying support eventually closed down at $50.23 with a loss of -0.06% for the day. The stock had closed at $50.26 on the previous day. The total traded volume was 6,387,972 shares.
Teva Pharmaceutical Industries Limited (Teva) is a global pharmaceutical and drug company. The Companys generic products cover almost every major therapeutic area. The Company operates its business in two segments: Generic medicines, which manufactures and sells generic pharmaceutical products in several dosage forms, including tablets, capsules, injectables, inhalants, liquids, ointments and creams, and Specialty medicines, which delivers solutions to patients and providers via medicines, devices and services. Its Central Nervous System (CNS) portfolio includes Copaxone, Azilect and Nuvigil. Its main respiratory medicines include ProAir hydrofluoroalkane, QVAR and Duoresp Spiromax. Its oncology portfolio includes Treanda, Trisenox, Granix Synribo, Lonquex, Tevagrastim/Ratiograstim, Myocet, Trisenox and Eporatio. Its womens health portfolio includes ParaGard, Plan B One-Step OTC/Rx (levonorgestrel) and Zoely.